Advocacy
Make your voice heard. Learn about PDAB legislation and implementation processes across the country.
Legislation
Colorado: SB24-060
Exempts a prescription drug that is designated as a drug for a rare disease by the FDA from consideration by the Prescription Drug Affordability Board.
Passed Senate Committee on State, Veterans, & Military Affairs: 2/22/24 YEAS 3 NAYS 2
Referred to Senate Committee of the Whole
Scheduled for Second Reading: 4/1/24
Connecticut: SB 8
Creates a Prescription Drug Affordability Board.
Hearing Held: 3/12/24
Favorable Report from Committee on Human Services: 4/8/24 YEAS 17 NAYS 7
Favorable Report from Committee on Judiciary: 4/22/24 YEAS 24 NAYS 11
Illinois: HB 4472
Establishes the Health Care Availability and Access Board.
Assigned to Health Care Availability and Accessibility Committee
Iowa: HF 2408 / SF 2238
Creates a Prescription Drug Affordability Board
SF 2238
Referred to Health and Human Services Committee
Subcommittee assigned, not scheduled.
HF 2408
Referred to Commerce Committee
Maryland: HB 340 / SB 388
Requires the board to a process for setting upper payment limits for all purchases and payor reimbursements of prescription drug products in the State that the Board determines have led or will lead to affordability challenges.
SB388
Referred to Finance Committee
Heard in Committee: 2/7
HB340
Referred to Health and Government Operations Committee
Heard in Committee: 2/8
Maine: LD 1829
Expands authority of Prescription Drug Affordability Board to set upper payment limits referenced to Medicare price negotiations.
Referred to Committee on Health Coverage, Insurance and Financial Services
Divided Report: 2/1/24 YEAS 7 NAYS 4
Passed Senate: 3/27/24 YEAS 22 NAYS 13
Passed House: 3/28/24 YEAS 78 NAYS 66
Michigan: SB 483
Creates the prescription drug pricing board and prescription drug affordability stakeholder council.
Passed Senate: 10/4/23 – YEAS 20 NAYS 17
Referred to House Committee on Insurance and Financial Services
Nebraska: LB 833
Creates a Prescription Drug Affordability Board.
Referred to Banking, Commerce and Insurance Committee
Hearing Scheduled: 2/27
Rhode Island: S 2719 / H 8220
Creates the Rhode Island Drug Cost Review Commission.
S 2719
Referred to Senate Health and Human Services: 3/5/24
Committee Recommends Passage: 5/14/24
Passed Senate: 5/21/24
Referred to House HHS Committee: 5/23/24
H 8220
Referred to House Health and Human Services Committee: 5/6/24
Hearing Scheduled in House HHS Committee: 5/9/24
Vermont: S.98
Authorizes and directs the Green Mountain Care Board to evaluate the costs of prescription drugs.
Committee Discussion Held: 2/23/24
Passed as Amended by Committee on Health and Welfare: 3/26/24
Passed as Amended by Committee on Appropriations: 3/26/24
Passed Senate: 3/27/24 YEAS 23 NAYS 5
Virginia: HB 570 / SB 274
Establishes a Prescription Drug Affordability Board.
SB274
Reported from Commerce and Labor Committee: 2/5/24 YEAS 10 NAYS 5
Reported from Finance and Appropriations Committee: 2/8/24 YEAS 9 NAYS 6
Passed Senate: 2/13/24 YEAS 23 NAYS 16
Reported from House Labor and Commerce Committee: 2/20/24 YEAS 12 NAYS 10
Passed House: 2/23/24 YEAS 50 NAYS 47
VETOED by Governor: 4/8/24
HB570
Reported from Labor and Commerce: 2/1/24 – YEAS 12 NAYS 10
Reported from Appropriations Subcommittee on Health and Human Resources: 2/7 YEAS 5 NAYS 2
Passed House: 2/13/24 YEAS 52 NAYS 46
Reported from Commerce and Labor: 2/22/24 – YEAS 10 NAYS 5
Reported from Finance and Appropriations: 2/29/24 – YEAS 10 NAYS 4
Passed Senate: 3/5/24 – YEAS 15 NAYS 15
Implementation
Colorado Prescription Drug Affordability Board
Next Meeting: January 17, 2025 – 10AM MST
Agenda TBD
Previous Findings:
Trikafta – Not Unaffordable
Genvoya – Not Unaffordable
Enbrel – Unaffordable
Stelara – Unaffordable
Cosentyx – Unaffordable
The Board is considering plans for setting upper payment limits for drugs deemed unaffordable.
Maryland Prescription Drug Affordability Board
Next Board Meeting: January 27, 2025
Agenda TBD
At the May meeting, the PDAB selected six drugs for cost review:
Farxiga
Jardiance
Ozempic
Trulicity
Dupixent
Skyrizi
Data is currently being collected for the review and Board consideration is expected this fall.
Oregon Prescription Drug Affordability Board
Next Meeting: December 18 – 9:30AM PST
Draft Agenda
Register HERE
In June, the board voted to pause current assessments in order to reevaluate their process and data. Assessments are expected to resume in 2025.
Previous Findings:
Ozempic – May Cause Affordability Challenges (2/21)
Trulicity – May Cause Affordability Challenges (2/21)
Shingrix- Reviewed, No Motion to Add to List of Drugs That May Cause Affordability Challenges (2/21)
Inflectra – Removed from Affordability Review (5/15)
Skyrizi – Removed from Affordability Review (5/15)
© 2024 Value of Care Coalition
Washington, DC 20006